Intellectual Property India Publishes Patent Application for 'Formulation And Evaluation Of Orally Disintegrating Tablets Of Ondansetron' Filed by Dr. Navneet Verma; Rajiv Yadav; Dr. Yash Prashar; Kumarappan Chidambaram; Dr Shalini Kulshrestha; Julliyan Dilleban A; Dr. Jobin Jose; and Dr. Abhishek Nagar

MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202511116840 A) filed by Dr. Navneet Verma; Rajiv Yadav; Dr. Yash Prashar; Kumarappan Chidambaram; Dr Shalini Kulshrestha; Julliyan Dilleban A; Dr. Jobin Jose; and Dr. Abhishek Nagar, Moradabad, Uttar Pradesh, on Nov. 25, 2025, for 'formulation and evaluation of orally disintegrating tablets of ondansetron.'

Inventor(s) include Dr. Navneet Verma; Rajiv Yadav; Dr. Yash Prashar; Kumarappan Chidambaram; Dr Shalini Kulshrestha; Julliyan Dilleban A; Dr. Jobin Jose; and Dr. Abhishek Nagar.

The application for the patent was published on Jan. 9, under issue no. 02/2026.

According to the abstract released by the Intellectual Property India: "The present invention relates to an improved pharmaceutical composition of ondansetron in the form of orally disintegrating tablets exhibiting rapid disintegration, enhanced stability, improved taste masking, and superior bioavailability. The formulation comprises ondansetron as the active pharmaceutical ingredient, superdisintegrants selected from crospovidone and croscarmellose sodium in optimized ratios, directly compressible excipients including microcrystalline cellulose and mannitol, sweetening agents for taste masking, and suitable lubricants. The tablets are prepared by direct compression method without requiring freeze drying or complex manufacturing processes. The formulation achieves complete disintegration within 30 seconds in the oral cavity, provides immediate release characteristics with more than 90% drug release within 15 minutes, maintains structural integrity during packaging and handling, and masks the bitter taste of ondansetron effectively. The invention addresses the limitations of existing ondansetron formulations by providing a cost effective, patient friendly dosage form particularly suitable for pediatric and geriatric populations experiencing nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions."

Disclaimer: Curated by HT Syndication.